对先进的三阴性乳腺癌患者的各种治疗策略的有效性进行比较:一个总体审查
Xiaolan Ma1, Shubing Jia1, Tong Gao1
1Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Clinical pharmacology and therapeutics
|March 2, 2026
概括
萨西图祖马布戈维特干 (SG) 和三基利布与化疗 (TRI_CT) 显示了高级三阴性乳腺癌 (aTNBC) 的优异结果. 与传统化疗相比,这些向治疗改善了无进展生存 (PFS) 和整体生存 (OS).
科学领域:
- 在瘤学瘤学.
- 医学治疗学 医学治疗学
- 临床试验 临床试验
背景情况:
- 化疗 (CT) 是高级三阴性乳腺癌 (aTNBC) 的标准,但疗效不同.
- 像向疗法 (TT) 和免疫检查点抑制剂 (ICI) 这样的创新疗法正在出现.
- 对aTNBC的治疗策略缺乏一致的疗效数据.
研究的目的:
- 综合审查和比较TT,ICI和CT对aTNBC的疗效.
- 为患有aTNBC的患者确定最佳的第一线治疗选择.
- 为TNBC管理中的临床决策提供高质量的证据.
主要方法:
- 进行了PubMed和Embase的系统搜索,寻找截至2025年6月的元分析和RCT.
- 在aTNBC中分析了17个元分析和52个关于TT,ICI和CT疗效的RCT.
- 使用AMSTAR 2和GRADE等级评估证据质量,并遵守PRISMA指南.
主要成果:
- 与CT相比,TT和ICI都显著改善了无进展生存期 (PFS).
- 向疗法 (TT) 显示总体存活率 (OS) 优于CT.
- 亚组分析显示,单独治疗sacituzumab govitecan (SG) 和结合化疗 (TRI_CT) 的trilaciclib显著改善了PFS和OS,而不是单独CT.
结论:
- 建议使用sacituzumab govitecan (SG) 单疗法和trilaciclib结合化疗 (TRI_CT) 作为aTNBC的第一线治疗方法.
- 这一综合性审查提供了高质量的,可信的证据,支持这些TT战略.
- 这些发现支持转向向治疗,以改善aTNBC患者的治疗结果.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
9.9K
09:29Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
19.8K
相关概念视频
Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
